MDxHealth Suspends Annual Guidance Amid Sales Turnover
The diagnostics firm will reorganize its sales force to address falling test volumes after a disappointing third quarter.
Updated on Oct. 15, 2026 in Economic Indicators
Live Poll
Do you trust companies to meet their financial goals after losing key staff members?
Irvine-based MDxHealth reported preliminary third quarter 2026 revenue of $22.7 million and suspended its full-year revenue guidance of $110-115 million. The diagnostic testing firm cited significant sales force turnover following the discontinuation of its Resolve mdx operation.
Why it matters
The company’s failure to meet revenue targets highlights the operational risks inherent in sudden sales force attrition following service line discontinuations. Operators must balance cost-cutting measures like product phase-outs with the potential impact on field-level execution and customer retention.
MDxHealth reported preliminary third quarter revenue of $22.7 million and holds $31.7 million in cash as of September 30, 2026. Tissue-based test volumes reached 11,232 units, down 11% year-over-year, while liquid-based volume hit 11,792 units.
The players
MDxHealth
An Irvine-based diagnostics company that provides tissue-based and liquid-based testing services.
The details
The revenue shortfall stems from unexpected turnover in the firm's sales force triggered by the decision to discontinue the Resolve mdx operation. To address this, the company is actively fortifying its sales territories to restore consistent operational execution. The firm suspended its $110-115 million full-year guidance as it works to stabilize the sales organization.
Timeline
September 30, 2026: The third quarter concluded.
October 15, 2026: The company announced its preliminary revenue and guidance suspension.
November 12, 2026: The company will report its full third quarter results.
Market Landscape
The suspension of full-year 2026 revenue guidance reflects a significant deviation from the company's established financial roadmap. It highlights the vulnerability of service-dependent businesses when restructuring operations like the Resolve mdx discontinuation leads to sudden personnel loss.
Business owners managing product-line transitions should monitor the effect of staff turnover on key performance metrics to prevent similar revenue gaps. Keep a close watch on the November 12 earnings call for further details on the company's recovery strategy and financial health.
The takeaway
Sudden sales team attrition during operational shifts creates immediate revenue risk that can necessitate a full suspension of annual guidance. Operators should track staffing stability alongside service-line changes and monitor the November 12, 2026, earnings report for management's revised growth strategy.
Further reading
For more on industry performance trends, see Economic Indicators.
Live Poll
Do you trust companies to meet their financial goals after losing key staff members?
